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Abstract
To identify molecular markers with predictive value for the progression of superficial bladder cancer we used the 
differential hybridization analysis approach. Since primary tumor material is heterogeneously composed of subpopulations 
that are poorly characterized, we used in this study a rat progression model system that phenotypically and cytogenetically 
resembles human superficial bladder cancer. In the differential hybridization analysis we compared the mRNA populations 
of low and high metastatic tumor lines. We observed an overexpression of ferritin Heavy chain (ferritin H) in the tumor line 
with the lower metastatic capacity and better differentiated phenotype. The exact clinical relevance for the differential 
expression of ferritin H in human bladder cancer remains to be determined.
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1. Introduction
An important issue in the management of superfi­
cial transitional cell carcinoma (TCC) of the bladder 
is to identify those patients that are at risk for pro­
to invasive disease. Since primary tumor 
material is usually heterogeneously composed of sub
populations are poorly characterized, it is not
suitable to identity TCC progression markers. The
identification of such requires a tumor
model system in which the different stages of tumor 
progression are represented.
* Corresponding author. Public Health Research Institute, De­
partment of Molecular Genetics, 455 First Avenue, New York, 
NY 10016, USA. Fax: + 1 212 57B0804; E-mail: 
vet@phri.nyu.edu
In this study a rat bladder tumor model system 
(RBT) is used that phenotypically and cytogenetically 
resembles human superficial TCC [1]. Two sponta­
neously arisen bladder tumors (in ACI rats) RBT 323 
and RBT 157, were serially transplanted. In the fifth 
transplant generation the RBT 323 becomes metastatic 
to the lungs in more than 90% of animals. The 
metastatic ability of the RBT 157 tumor changes from 
low to intermediate (50% of the rat have lung metas- 
tases) in the fourth passage. The tumor doubling time 
of the RBT 323 tumor decreased from 13 days to 
3.5-4 days, while the tumor doubling time of the 
RBT 157 tumor remained almost unchanged. Both 
tumor lines initially resembled grade II TCC. How­
ever, while the histological pattern of the RBT 157 
remained essentially unchanged, the RBT 323 tumor 
progressed to a grade III tumor in the third passage 
[1]. In order to identify genes that are associated with
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the progression of superficial bladder cancer we ap-
ysis to compare the mRNA levels of the RBT 323 
with the RBT 157 line, two lines that differ in their 
metastatic capacity. The cDNA clones that detected 
differentially expressed genes were further evaluated 
for their relationship to the metastatic phenotype by 
means of Northern blot analyses. The cDNA clones 
of interest were sequenced and the resulting nu­
cleotide sequences were compared to nucleotide 
database to search for homology with known genes.
2. Materials and methods
2.1. Tumor specimens
Tumor material from a rat bladder tumor model 
system (RBT) [1] was used in this study (Table 1). 
Transplant passage #10 of the highly metastatic line 
RBT 323 and passage #1  of the moderate metastatic 
line RBT 157 were used for the differential hy-
Table 1
Growth characteristics o f rat bladder tumor lines
Tumor passage Tumor doubling time u M étastasésb
RBT323 ND 0 /1
Passage 1 ND 0 / 6
Passage 2 13 .4 (1 .4 ) 0 / 8
Passage 3 11 .8(1 .2) 1 /1 0
Passage 4 5.9 (1.0) 0 / 9
Passage 5 5.7 (0.3) 3 / 7
Passage 6 4.4 (0.1) 1 1 /1 3
Passage 8 3.8 (0.2) 1 5 /1 5
Passage 10 3.7 (0.2) 9 / 9
Passage 12 4.2 (0.3) 1 9 /2 2
Passage 13 3.3 (0.3) 6 / 6
Passage 15 4.3 (0.3) 5 / 6
Passage 16 4.0 (0.3) 6 / 6
RBT 157 ND 0 /1
Passage 1 11.2(0 .8) 0 / 4
Passage 2 ND 1 /7
Passage 3 10.5 (1.1) 2 / 9
Passage 4 8.2 (0.3) 5 / 8
Passage 6 9.5 (1.8) 2 / 6
9  %
‘ Tumor doubling time in days, SEM in brackets (ND, not 
determined).
b Number o f  rats with lung métastasés/tota l number of rats 
implanted with respective tumor passage.
bridization experiments. In order to check the rele­
vance of the selected clones passages 1, 2, 8, 9, 15 
and 16 of the RBT 323 line and passage 1 and 6 of 
the RBT 157 line were used.
2.2. Construction of cDNA libraries
A directionally cloned cDNA library was con­
structed using polyadenylated cytoplasmic RNA from 
the highly metastatic RBT323 line, passage #10. 
Poly(A + )RNA (5 /xg) was fractionated from total 
RNA by oligo(dT)-cellulose chromatography and to­
tal RNA was isolated using the lithium chloride/urea 
procedure [2]. First strand cDNA was synthesized by 
using an oligo(dT) primer-adaptor (Promega) contain­
ing a NOT-1 site 5' to the oligo(dT) tail. Second 
strand cDNA synthesis was performed using the pro­
cedures described by Gubler and Hofman [3]. The 
cDNA was blunt ended by using T4-DNA poly­
merase (10 U). After purification using micro collo­
dion bags (Sartorius GmbH), EcoRl linkers (1 /ng, 
Stratagene) were ligated to the blunt ended cDNA by 
means of T4-DNA ligase, followed by digestion with 
NOT-1 and EcoRl restriction endonucleases. The 
digested linkers were separated from the cDNA by 
means of PurElute™ agarose gel electrophoresis (In- 
vitrogen) and the cDNAs with the desired size range 
(0.5-10 kb) were isolated from the agarose. Electroe­
lution of the cDNA from the agarose was performed 
using the Geneluter™ electroelution system (Invitro- 
gen). Subsequently the ds cDNA was ligated in the 
Lambda Zap-II cloning vector (Stratagene), inserted 
into the phage particles using Promega Packagene 
Lambda DNA Packaging System and transformed to 
XL-1 Blue E. coli bacteria.
2.3. Differential screening o f the cDNA library
For the differential screening of the RBT 323/10 
cDNA library, 36000 recombinant phages were
plate were taken on nitrocellulose by incubation dur­
ing 1, 3, 10 and 30 min, respectively. The filters were 
next lysed according to Sambrook et al. [4]. Hy­
bridization was performed according to Hanahan and 
Meselson [5] in 40% formamide at 42°C during 60 
hours. For the differential screening, probes represen­
tative for the RBT 323/pass ■ 10 and RBT 157/pass
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puter assisted comparison studies of the sequences pressed; 16 overexpressed in the RBT 323 line and 6
were performed with the E M B L  and Genbank 
cleotide sequence databases.
3. Results
overexpressed in the RBT 157 line. These 22 selected 
cDNA clones were further evaluated using Northern
blots containing 10 pug o f RBT 157 /1 , RBT 323 /1  
and RBT 3 2 3 /1 0  RNA. The expression pattern of 
the most significant clone pV13 is shown in Fig. 2A.
3.1. Differential screening 3.2. Expression pattern o f pV13
A cDNA library was constructed  from  the mRNA 
of the highly metastatic line  RBT 323/p a ssa g e  10.
The complexity of the library  was 4.3 • 105 recombi­
nant clones and 36000 recom binant phages from the (Fig. 2A). The correlation of clone pV13 expression
Clone pV13, is clearly overexpressed in RBT 
157/1, the line with the lowest metastatic capacity. 
pV13 detects a single transcript of approx. 1.1 kb
primary library were plated. Replica filters were dif­
ferentially screened using radioactively labeled cDNA
with metastatic capacity was further studied by means 
of Northern blot analysis of more passages of the rat
probes derived from p o ly -A + RNA o f  the RBT progression model (Fig. 2B). The passages 1 and 6 of
323 /pass.lO  (high m etas ta tic )  and the RBT the RBT 157 line, with the moderate metastatic ca-
157/pass.l (low metastatic). Extensive comparison pacity, show both an higher expression level of pV 13
of the resulting autoradiograms (Fig. 1) revealed 22 
cDNA clones that seem ed to  be differentially ex­
compared to the tested passages of the RBT 323 line, 
with the high metastatic capacity. As a control we
(A)
MW (kb)
6.7
4.3 -
2.3
2.0
1
pV13
2 3
.■ /ri il
(B)
MW (kb)
6.7 -
4,3 *
2.3 - 
2.0 -
6,7 -
4.3 -
2.3
2.0
RBT 323
1 2 15 16
RBT 157 
1
Fig. 2. 10 /xg of total RNA was glyoxylated, size fractioned on 1% agarose gels and transferred to Hybond-N+ nylon membranes. A. 
Secondary screening of the selected cD N A  clone pV 13 on the passages RBT 157/1 (1), RBT 3 2 3 /1  (2) and RBT 3 2 3 /1 0  (3). Probe 
pV13 was made of the differentially expressed cD N A  clone by random prime labelling reactions. B. Correlation of clone pV13 with 
metastatic phenotype. The probe w as made, using the isolated insert of cDNA clone pV13, by random labelling reaction. rRNA was used 
as an internal control for the am ount o f  RNA loaded (shown in lower panel (B)).
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studied the expression of pV13 in Dunning R-3327 
rat prostatic tumors [8] and in normal rat prostate (in
correlation between ferritin H expression and a num­
ber of differentiation shown by others
normal bladder insufficient RNA was isolated from [18,19], is corroborated in this study by the overex-
the tiny layers of urothelium). The higher expression 
of pV13 in the sublines with lower metastatic capac­
ity, as seen for the bladder tumor model system, was 
confirmed and in normal rat prostate no expression of 
pV13 was observed (data not shown).
3.3. DNA sequence analysis o f pV13
pression of ferritin H in the better differentiated 
tumor line RBT 157. In smooth muscle cells it is
proposed that cAMP promotes ferritin H expression 
resulting in both growth arrest and an enhanced 
differentiated phenotype [20].
The exact biological consequences of altered fer­
ritin subunit composition are not well understood. It
To obtain further information on the cDNA clone, 
the nucleotide sequences were determined using the 
Sequenase Version 2.0 sequence system. Computer- 
assisted comparison of the resulting nucleotide se-
may result in modulation of the iron binding capacity 
of ferritin and ultimately, the regulatory pools of free 
iron [21,11]. An enrichment for the ferritin H subunit 
leads to more efficient iron detoxification and cellular
protection against free formation [22]. An-
quences with the EMBL and Gen bank nucleotide other mechanism underlying the regulation of ferritin
sequence databases revealed that p V 13 is highly ho­
mologous to the Rat Ferritin Heavy chain gene (97%) 
[9] and the Mouse Ferritin Heavy chain (94%) [10].
expression has been extensively studied and is ex­
erted posttranscriptionally by specific mRNA-protein 
interaction between the iron-regulating protein (IRE­
BP) and Iron-Responsive Elements (IREs) contained 
in the 5 'untranslated region of ferritin. Iron inacti-
4. Discussion vates the cytoplasmic IRE-BP, thereby preventing its
In search of new molecular markers with predic­
tive value for the progression of superficial TCC, we
binding to the IRE and consequently derepressing 
ferritin translation [23].
It should be emphasized that the mechanisms un-
compared two different tumor lines of a rat TCC derlying the altered subunit composition of ferritin in
model system at the level of gene expression using 
differential hybridization analysis. We observed an 
overexpression of ferritin H in the RBT 157 tumor 
line which displays the lowest metastatic capacity 
and the best differentiated phenotype.
Ferritin H combines with the ferritin L subunit to
neoplastic cells are not elucidated. Ferritin H is lo­
cated on human chromosome 11 [24], near 11 q 13 
[25], a region that is sometimes amplified in bladder 
cancer [26]. We have determined that the ferritin H
gene is not within the i 
shown).
on 11 q 13 (data not
form the iron storage protein ferritin [11]. Ferritin Cytogenetic analysis of the RBT lines showed that
H-rich molecules take up and release iron more read­
ily than L-rich molecules, that are more suited for 
long-term storage [12]. A relationship between fer-
both of the independently arisen tumors exhibit loss 
of chromosome 5 [1]. Rat chromosome 5 is syntenic 
to the major portion of human chromosome 9 (p23-
ritin and cancer been since serum qter) a chromosome that is commonly lost in human
ferritin is frequently elevated in patients with cancer 
[13,14]. Some neoplastic cells also exhibit a remark-
TCC. The more RBT 323 has
considerably more cytogenetic changes compared to
ably altered ferritin subunit composition (i.e enrich­
ment for the heavy chain subunit) as compared to 
their normal counterparts [15,16]. A direct association
RBT 157. Due to the fact that the 
nomic map of human and rat is rather restricted [27]
it is difficult to speculate about the potentially
between oncogenic transformation and ferritin syn- relevant to the observed cytogenetic changes
thesis has been suggested, since the adenovirus E l A 
oncogene specifically represses ferritin H expression 
[17]. The observed down regulation of ferritin H 
expression in the more malignant tum or line RBT 
323 is in concordance with this observation. The
Our findings show a correlation of ferritin H over­
expression with lower metastatic capacity and better 
differentiated phenotype in a rat bladder tumor model 
system. We are currently investigating the value of 
differential exoression of ferritin H as a prognostic
44 J.A.M. Vet et al. / Biochimica et Biophysica Acta 1360 ( 1997) 39-44
marker in human bladder cancer using quantitative 
comparative Polymerase Chain Reaction.
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